Autres langues ZIM Laboratories Limited

Actions

ZIMLAB

INE518E01015

Produits pharmaceutiques

Temps Différé Bombay S.E. Autres places de cotation 09:45:00 24/07/2026			Varia. 5j.	Varia. 1 janv.
120,00 ^INR	-0,04%		-4,34%	+66,92%

21/05	Dubai Investments annonce la signature de 7 protocoles d'accord stratégiques par Globalpharma	RE
20/05	Transcript : ZIM Laboratories Limited, Q4 2026 Earnings Call, May 20, 2026

Autres langues

21/05	Dubai Investments says Globalpharma signs 7 strategic MoUs
20/05	ZIM Laboratories' Consolidated Profit Declines in Fiscal Q4; Shares Slide 4%
19/05	Zim Laboratories gets marketing authorization for dabigatran etexilate capsules in Italy, Europe
19/05	ZIM Laboratories Limited Announces Grant of Marketing Authorization (MA) for Dabigatran Etexilate (75 Mg, 110 Mg & 150 Mg) Capsules in Italy, Europe
19/05	ZIM Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026
19/05	Zim Laboratories March-quarter consol net profit 37.4 mln rupees
13/03	ZIM Laboratories Limited announced that it has received INR 349.99995 million in funding from Florintree Trinex LLP
12/02	ZIM Laboratories To Set Up Wholly Owned Subsidiary In Chile
12/02	ZIM Laboratories Posts Higher Consolidated Profit Climbs in Fiscal Q3
11/02	ZIM Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025
02/02	ZIM Laboratories Limited Announces Executive Changes, Effective February 2, 2026
21/01	ZIM Laboratories Limited announced that it expects to receive INR 349.99995 million in funding
15/01	Zim Laboratories to consider fund raising via securities issuance
03/12	Indian Equities Ease on Wednesday as Rupee Weakness, Foreign Outflows Persist
03/12	ZIM Laboratories Gets Indian Regulator's Nod for Naproxen + Esomeprazole Capsules
03/12	ZIM Laboratories Limited Receives Approval from Central Drugs Standard Control Organization
12/11	ZIM Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025
07/08/25	ZIM Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025
07/08/25	ZIM Laboratories Limited Approves Closure of ZIM Laboratories Middle East DMCC
04/08/25	Zim Laboratories gets marketing authorization for Tamsulosin + Dutasteride capsules in Australia
04/08/25	ZIM Laboratories Limited Receives Marketing Authorization for Tamsulosin Hydrochloride and Dutasteride Capsules in Australia
21/07/25	ZIM Laboratories Receives Australian Marketing Approval for Migraine Drug
21/07/25	ZIM Laboratories Limited Receives First Marketing Authorization in Australia for Rizatriptan Benzoate Orally Disintegrating Films Via Zimtas Pty Ltd
27/06/25	Zim Laboratories Limited Approves to Appoint of Ashok Bhatia as an Independent Director
19/06/25	SIA "ZIM Laboratories Limited" announced that it has received ?0.3 million in funding from ZIM Laboratories Limited